PuSH - Publication Server of Helmholtz Zentrum München: Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Reiner, J.* ; Mohebali, N.* ; Kurth, J.* ; Witte, M.* ; Prehn, C. ; Lindner, T.* ; Berlin, P.* ; Elleisy, N.* ; Förster, R.H.* ; Cecil, A. ; Jaster, R.* ; Adamski, J. ; Schwarzenböck, S.M.* ; Vollmar, B.* ; Krause, B.J.* ; Lamprecht, G.*

Glucagon-like peptide-2 pharmacotherapy activates hepatic Farnesoid X receptor-signaling to attenuate resection-associated bile acid loss in mice.

Mol. Metab. 95:102121 (2025)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

The Glucagon-like peptide-2 (GLP-2) analogue teduglutide is used clinically for the treatment of short bowel syndrome and intestinal failure occurring after extensive intestinal resection. A recently discovered effect of GLP-2 treatment is the inhibition of gallbladder motility and increased gallbladder refilling. However, the impact of these two GLP-2-characteristic effects on bile acid metabolism in health and after intestinal resection is not well characterized. To study effects of teduglutide treatment, we combined the selenium-75-homocholic acid taurine (SeHCAT) assay with novel spatial imaging in healthy mice and after ileocecal resection (ICR mice) and associated the results with clinical stage targeted bile acid metabolomics as well as gene expression analyses. ICR mice had virtual complete intestinal loss of secondary bile acids, and an increased ratio of 12α-hydroxylated vs. non-12α-hydroxylated bile acids, which was attenuated by teduglutide. Teduglutide promoted SeHCAT retention in healthy and in ICR mice. Acute concentration of the SeHCAT-signal into the hepatobiliary system was observed. Teduglutide induced significant repression of hepatic cyp8b1 expression, which was associated with induction of MAF BZIP Transcription Factor G. The data suggest that GLP-2-pharmacotherapy in mice significantly slows bile acid circulation primarily via hepatic Farnesoid X receptor-signaling.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Bile Acid Metabolome ; Cyp8b1 ; Glucagon-like Peptide-2 ; Ileocecal Resection ; Sehcat ; Short Bowel Syndrome; Short-bowel Syndrome; Growth-factor-i; Serum 7-alpha-hydroxy-4-cholesten-3-one; Malabsorption; Teduglutide; Proliferation

ISSN (print) / ISBN 2212-8778

e-ISSN 2212-8778

Journal Molecular Metabolism

Quellenangaben Volume: 95, Article Number: 102121

Publisher Elsevier

Publishing Place Amsterdam

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) CF Metabolomics & Proteomics (CF-MPC)
Institute of Experimental Genetics (IEG)

Grants Rostock University Medical Center Clinician Scientist Program
Else Kroener-Fresenius-Stiftung